Skip to main content

Remote Job Finders (RJF)

Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis

Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 18–20% royalties on net sales.

BMS’ neuro renaissance was built on back of Celgene mega-merger

Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychiatric diseases, with a “continuum of care” mindset.
Scroll to top